NEW YORK – Point-of-care diagnostic company MBio Diagnostics announced Wednesday it has merged with Brava Diagnostics.
Financial and other terms of the deal were not disclosed.
Brava will operate as the human in vitro diagnostics division of MBio to develop a portfolio of point-of-care tests for time-critical conditions, MBio said in a statement. Currently there are product development programs for COVID-19, host-response biomarkers, and cardiac markers.
Both companies are based in Boulder, Colorado.